Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo.
Rajamani BM, Illangeswaran RSS, Benjamin ESB, Balakrishnan B, Jebanesan DZP, Das S, Pai AA, Vidhyadharan RT, Mohan A, Karathedath S, Abraham A, Mathews V, Velayudhan SR, Balasubramanian P. Rajamani BM, et al. Among authors: benjamin esb. Front Pharmacol. 2023 May 31;14:1187066. doi: 10.3389/fphar.2023.1187066. eCollection 2023. Front Pharmacol. 2023. PMID: 37324449 Free PMC article.
Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.
Rajamani BM, Benjamin ESB, Abraham A, Ganesan S, Lakshmi KM, Anandan S, Karathedath S, Varatharajan S, Mohanan E, Janet NB, Srivastava VM, Ramachandran Velayudhan S, Kulkarni UP, Devasia AJ, Fouzia NA, Korula A, George B, Srivastava A, Mathews V, Balasubramanian P. Rajamani BM, et al. Among authors: benjamin esb. Sci Rep. 2020 Nov 26;10(1):20640. doi: 10.1038/s41598-020-77140-9. Sci Rep. 2020. PMID: 33244077 Free PMC article.
BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib.
Benjamin ESB, Ravindra N, Rajamani BM, Anandan S, Kausalya B, Veldore V, Mathews V, Velayudhan SR, Balasubramanian P. Benjamin ESB, et al. Leuk Lymphoma. 2021 Jun;62(6):1528-1531. doi: 10.1080/10428194.2021.1872074. Epub 2021 Jan 22. Leuk Lymphoma. 2021. PMID: 33478278 Free PMC article. No abstract available.
NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy.
Pai AA, Mohan A, Benjamin ESB, Illangeswaran RSS, Xavier Raj I, Janet NB, Arunachalam AK, Kavitha ML, Kulkarni U, Devasia AJ, Fouzia NA, Abraham A, Srivastava A, George B, Mathews V, Korula A, Balasubramanian P. Pai AA, et al. Among authors: benjamin esb. Pharmgenomics Pers Med. 2021 Oct 2;14:1303-1313. doi: 10.2147/PGPM.S325813. eCollection 2021. Pharmgenomics Pers Med. 2021. PMID: 34629890 Free PMC article.
Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs.
Benjamin ESB, Vinod E, Illangeswaran RSS, Rajamani BM, Vidhyadharan RT, Bagchi A, Maity A, Mohan A, Parasuraman G, Amirtham SM, Abraham A, Velayudhan SR, Balasubramanian P. Benjamin ESB, et al. Cell Signal. 2024 Apr;116:111067. doi: 10.1016/j.cellsig.2024.111067. Epub 2024 Jan 27. Cell Signal. 2024. PMID: 38281615
Efficient deletion of microRNAs using CRISPR/Cas9 with dual guide RNAs.
Ijee S, Chambayil K, Chaudhury AD, Bagchi A, Modak K, Das S, Benjamin ESB, Rani S, Paul DZ, Nath A, Roy D, Palani D, Priyanka S, Ravichandran R, Kumary BK, Sivamani Y, S V, Babu D, Nakamura Y, Thamodaran V, Balasubramanian P, Velayudhan SR. Ijee S, et al. Among authors: benjamin esb. Front Mol Biosci. 2024 Apr 2;10:1295507. doi: 10.3389/fmolb.2023.1295507. eCollection 2023. Front Mol Biosci. 2024. PMID: 38628442 Free PMC article.